Alteration in diurnal and nocturnal melatonin serum level in patients with chronic heart failure

Annals of Agricultural and Environmental Medicine

Volumn 20, Issue 4, 2013, Pages 745-748

  Dzida, Grzegorz ^a   Prystupa, Andrzej ^a   Lachowska Kotowska, Patrycja ^a   Kardas, Tobiasz ^a   Kamieński, Piotr ^a   Kimak, Elzbieta ^a   Hałabiś, Magdalena ^a   Kiciński, Paweł ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Chronic heart failure; Melatonin; NYHA

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; MELATONIN;

AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART FAILURE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; MALE; NEW YORK HEART ASSOCIATION CLASS; PATHOGENESIS; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CIRCADIAN RHYTHM; HEART FAILURE; HUMANS; MELATONIN; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84891066119     PISSN: 12321966     EISSN: 18982263     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Berry C, Murdoch D, McMurray J. Economics of chronic heart failure. Eur J Heart Fail. 2001; 3(3): 283-291.
2. Komajda M, Pousset F, Isnard R, Lechat P. The role of the neurohormonal system in heart. Heart 1998; 79(Suppl 2): 17-23.
3. Zhdanova IV, Tucci V. Melatonin, circadian rhythms, and sleep. Curr Treat Options Neurol. 2003; 5(3): 225-229.
4. Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, et al. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess. 2004; 108: 1-7.
5. Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011; 50(3): 261-266.
6. Duncker DJ, Verdouw PD. Has Melatonin a Future as a Cardioprotective Agent? Cardiovasc Drugs Ther. 2001; 15: 205-207.
7. Patel V, Upaganlawar A, Zalawadia R, Balaraman R. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: A biochemical, electrocardiographic and histoarchitectural evaluation. Eur J Pharmacol. 2010; 644(1-3): 160-168.
8. Mukherjee R, Banerjee S, Joshi N, Singh PK, Baxi D, Ramachandran AV. A combination of melatonin and alpha lipoic acid has greater cardioprotective effect than either of them singly against cadmiuminduced oxidative damage. Cardiovasc Toxicol. 2011; 11(1): 78-88.
9. Ekmekcioglu C, Haslmayer P, Philipp C, Mehrabi MR, Glogar HD, Grimm M, et al. Expression of the MT1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res. 2001; 21(1): 85-91.
10. Ekmekcioglu C, Thalhammer T, Humpeler S, Mehrabi MR, Glogar HD, Hölzenbein T, et al. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res. 2003; 35(1): 40-44.
11. Tan DX, Chen LD, Poegeller B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J. 1993; 1: 57-60.
12. Scheer FA, Van Montfrans GA, Van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004; 43: 192-197.
13. Arangino S, Cagnacci A, Angiolucci M, Vacca AM, Longu G, Volpe A, et al. Effects of melatonin on vascular reactivity, catecholamine levels and blood pressure in healthy men. Am J Cardiol. 1999; 83: 1417-1419.
14. Salie R, Harper I, Cillie C, Genade S, Huisamen B, Moolman J, et al. Melatonin protects against ischaemic-reperfusion myocardial damage. J Mol Cell Cardiol. 2001; 33: 343-357.
15. Oz E, Ilhan MN. Effects of melatonin in reducing the toxic effects of doxorubicin. Mol Cell Biochem. 2006; 286(1-2): 11-5.
16. Reiter RJ, Manchester LC, Fuentes-Broto L, Tan DX. Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. J Hypertens. 2010; 28(Suppl 1): 7-12.
17. Stehle JH, Foulkes NS, Molina CA, Simonneaux V, Pévet P, Sassone-Corsi P. Adrenergic signals direct rhythmic expression of transcriptional repressor CREM in the pineal gland. Nature 1993; 365: 314-320.
18. Girotti L, Lago M, Ianovsky O, Elizari MV, Dini A, Lloret SP, et al. Low Urinary 6-Sulfatoxymelatonin Levels in Patients with Severe Congestive Heart Failure. Endocrine. 2003; 22(3): 245-248.
19. Arzt M, Young T, Finn L, Skatrud JB, Ryan CM, Newton GE, et al. Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. Arch Intern Med. 2006; 166: 1716-1722.
20. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347: 161-167.
21. Stanek B, Frey B, Hülsmann M, Berger R, Sturm B, Strametz-Juranek J, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 2001; 38: 436-442.
22. Hammond HK. Mechanisms of myocardial beta-adrenergic receptor desensitization in heart failure. Circulation. 1993; 87: 454-63.
23. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994; 23: 570-578.
24. Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl. J Med. 1990; 323: 236-241.
25. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. Creative protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol. 2006; 109(2): 248-256.
26. Dominguez-Rodriguez A, Garcia-Gonzalez M, Abreu-Gonzalez P, Ferrer J, Kaski JC. Relation of nocturnal melatonin levels to c-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2006; 97: 10-12.
27. Dominguez-Rodriguez A, Kaski JC, Abreu-Gonzalez P, Garcia-Gonzalez M. Cross-talk between C-reactive protein and light/dark variations. Int J Cardiol. 2007; 120(1): 130.